The content of our website is not intended for persons resident, or partnerships or corporations organised or incorporated inside the United States (“US Residents”). UBP does not market, solicit or promote its services inside the jurisdiction of the United States at any time. The content provided on the UBP website is intended to be used for general information purposes only. Therefore, nothing on this website is to be construed as an investment recommendation or an offer to buy or sell any security or investment product, nor as a guarantee or the future performance of any security or investment product.
To browse on UBP.com, please confirm that you are not a US resident.
Equity Analyst
Geneva, Svizzera
English, French
Pierre Corby è specialista in investimenti per il comparto Healthcare nel team dei servizi di consulenza di UBP a Ginevra, dove è entrato nel 2019.
Ha alle spalle 20 anni di esperienza nei mercati azionari e nelle scienze mediche. Prima di entrare in UBP, ha lavorato per 13 anni come analista sell-side nel campo delle scienze della vita a Parigi per diversi broker e, in particolare, ha partecipato all’offerta pubblica iniziale di Moderna a fine 2018. Prima di passare alla finanza, ha lavorato come ricercatore specializzato in biologia molecolare e virologia per l’Istituto Pasteur di Hong Kong e per un’azienda privata di biotecnologia in Francia.
Si è laureato all’Ecole de Management di Grenoble e ha conseguito una laurea in biologia molecolare e cellulare all’Université Joseph Fourier, anch’essa a Grenoble.
22.11.2021
In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.
14.04.2021
UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.
